BUFFALO BIOLABS, LLC — Department of Health and Human Services SBIR Phase II: Aberrant functioning of proteins within stress response pathways (e.g. p53, NF-B, heat sho
BUFFALO BIOLABS, LLC — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,496,764
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- NAICS
- —
- Place of performance
- NY
- Period
- —
Description
Aberrant functioning of proteins within stress response pathways (e.g. p53, NF-B, heat shock response) are prominent features in many cancer types. Such alterations have been associated with poor response of tumors to conventional antitumor treatments. This is true for such cancers as non-small cell lung cancer, hepatocellular carcinoma, advanced prostate cancer, renal cell carcinoma and glioblastoma multiforme. Targeted therapies against these alterations may restore tumor response to treatment and, thus,improve clinical outcome. Multifunctional agents, such as the Curaxin to be studied in the context of this contract, have the potential to be more effective than drugs that target single pathways since they decrease the likelihood of tumors finding ways tocircumvent their effects unlike single function agents where one mutation or inactivation of a component of the targeted pathway would make tumors less sensitive to treatment.